Best Pharmaceuticals for Children Act

Pub. L. 107–109

US Codex doesn’t hold the enacted text of this law — the public-law corpus runs from the 113th Congress (2013) onward. What it changed in the U.S. Code, reconstructed from the credit notes, is listed below.

14 sections of the Code credited to this law, found between Public Law 106-580 and Public Law 107-136.

• 21 U.S.C. § 321 — Definitions; generally
• 21 U.S.C. § 355 — New drugs
• 21 U.S.C. § 355a — Pediatric studies of drugs
• 21 U.S.C. § 355b — Adverse-event reporting
• 21 U.S.C. § 379h — Authority to assess and use drug fees
• 21 U.S.C. § 393a — Office of Pediatric Therapeutics
• 42 U.S.C. § 282 — Director of National Institutes of Health
• 42 U.S.C. § 284k — Clinical research
• 42 U.S.C. § 284l — Enhancement awards
• 42 U.S.C. § 284m — Program for pediatric studies of drugs
• 42 U.S.C. § 285a-2 — 285a–2. Special authorities of Director
• 42 U.S.C. § 290b — Establishment and duties of Foundation
• 42 U.S.C. § 284m–1 — Pediatric Advisory Committee
• 42 U.S.C. § 285a–2 — Special authorities of Director